晚期卵巢癌患者应用顺铂腹腔灌注联合多西他赛静脉化疗的临床研究被引量：14

下载PDF

导出

摘要目的探讨顺铂腹腔灌注联合多西他赛静脉化疗在晚期卵巢癌患者中的应用价值。方法选取该院2010年2月至2012年2月收治的晚期卵巢癌患者67例,根据其化疗方案分为对照组32例与观察组35例,对照组患者采用顺铂联合多西他赛单纯静脉化疗方案,观察组患者给予顺铂腹腔灌注联合多西他赛静脉化疗方案。结果两组患者的近期治疗有效率、复发率及毒副反应发生率比较,差异无统计学意义(P>0.05),但观察组患者的无进展生存期(TTP)与总生存时间(OS)均显著优于对照组,差异有统计学意义(P<0.05)。结论晚期卵巢癌患者采用顺铂腹腔灌注联合多西他赛静脉化疗可明显延长其生存时间,与顺铂联合多西他赛单纯静脉化疗比较具有显著优势。

作者张瑜

机构地区四川省凉山州第一人民医院妇产科

出处《检验医学与临床》 CAS 2016年第11期1539-1541,共3页 Laboratory Medicine and Clinic

关键词晚期卵巢癌顺铂多西他赛腹腔灌注静脉化疗

分类号 R730.3 [医药卫生—肿瘤]

引文网络
相关文献

参考文献10

1杨静.中间性肿瘤细胞减灭术治疗中晚期卵巢癌后对铂类药物耐药性及患者生存期的影响[J].现代中西医结合杂志,2015,24(15):1665-1666. 被引量：8
2Borley J,Brown R. Epigenetic mechanisms and therapeu- tic targets of chemotherapy resistance in epithelial ovarian cancer[J]. Ann Med,2015,47(5) :359-369.
3Nagle CM, Dixon SC,Jensen A, et al. Obesity and survival among women with ovarian cancer:results from the Ovar- ian Cancer Association Consortium[J]. Br J Cancer, 2015, 113(5) 1817-826.
4黄丽红,俞超芹,翟东霞,柴周芳,沈慰,张丹英.多西他赛联合奈达铂治疗复发性浆液性卵巢癌的疗效观察[J].中国妇产科临床杂志,2015,16(1):65-67. 被引量：15
5张晶,胡泽成,陈忠东.静脉联合洛铂腹腔恒温循环热灌注化疗对晚期卵巢癌的疗效研究[J].中国医学创新,2015,12(11):1-4. 被引量：17
6张建女.顺铂、多西他赛静脉化疗在中晚期卵巢癌围手术期中的应用探讨[J].中国医药指南,2015,13(7):136-137. 被引量：4
7王俊芳,崔萍,毛莉,张延志,程丽娟.腹腔热灌注化疗、体外射频深部热疗、免疫治疗三位一体综合治疗在晚期卵巢癌中的临床应用[J].中国继续医学教育,2015,7(7):47-48. 被引量：8
8张群,杨麒麟.全身静脉和腹腔热灌注双途径化疗联合体外热疗治疗晚期卵巢癌的疗效观察[J].医学美学美容（中旬刊）,2015,24(2):28-29. 被引量：3
9Hirohashi Y,Torigoe T,Mariya TA,et al. HLA class I as a predictor of clinical prognosis and CTL infiltration as a predictor of chemosensitivity in ovarian cancer[J]. On- eoimmunology, 2015,4(5) : 100-107.
10谭文福,张帆.腹腔灌注联合静脉化疗治疗晚期卵巢癌疗效观察[J].武汉大学学报（医学版）,2015,36(1):66-68. 被引量：20

二级参考文献50

1刘秀峰,秦叔逵.洛铂的临床研究进展[J].临床肿瘤学杂志,2006,11(7):549-552. 被引量：53
2朱文科.腹腔加静脉化疗防治卵巢癌术后复发的临床疗效观察[J].中国肿瘤临床与康复,2006,13(5):450-451. 被引量：4
3魏薇,沈铿,赵丽红,曹阳.Fischer344大鼠上皮性卵巢癌动物模型的建立[J].首都医科大学学报,2007,28(1):52-55. 被引量：8
4l~ustin GJ, Quinn M, Thigpen T, et al. Re: New guide- lines to evaluate the response to treatment in solid tumors (ovarian cancer). Natl Cancer Inst, 2004, 96: 487-488.
5Li Chen. Ovarian cancer including fallopian tube cancer and pri- mary peritoreal cancer. NCCN Guidelines, 2014, 5:1 - 50.
6David SA, Paul TF, Kelli LR, et al. In vitro phase Ⅱ comparison of the cytotoxidty of a novel platinum analog, nedaplatin (254 - S), with that of cisplatin and carbopiatin against fresh, human o- varian cancers. Cancer Chemother Pharrnacol, 1997, 39: 493 - 497.
7Masashi K, Shigemi M, Takahumi N. Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combi- nation therapy as a second- line regimen for advanced esophageal cancer. Int J Clin Oncol, 2007, 12:224- 227.
8Mulier S,Claes J P,Dierieck V,et al.Survival benefit of adding Hyperthermic Intra PEritoneal Chemotherapy(HIPEC)at the different time-points of treatment of ovarian cancer:review of evidence[J].Curr Pharm Des,2012,18(25):3793-3803.
9Dharmadhikari N,Shah R,Jagannath P.Initial experience with hyperthermic intra peritoneal chemotherapy and cytoreductivesurgery[J].Indian J Cancer,2014,51(2):189-192.
10Wang Z,Tang X,Zhang Y,et al.Lobaplatin induces apoptosis and arrests cell cycle progression in human cholangiocarcinoma cell line RBE[J].Biomed Pharmacother,2012,66(3):161-166.